Real-World Data on Avelumab as 1L Maintenance Treatment
In this MEDtalk, Dr. Philippe Barthelemy, from the ICANS Institute in Strasbourg, discusses the AVENANCE study results with real-world data from France. The study confirms the effectiveness and safety of avelumab as a safe standard of care for patients with advanced urothelial carcinoma.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
